

# newsletter



Intoinworld Co., Ltd., a people-focused company.  
"From people to people, connecting the value of clinical research."

Intoinworld Co., Ltd. strives to be a bridge of trust between patients, investigators, and sponsors, ensuring that the value of medical innovation is safely delivered to people. Founded in 2015, we are a contract research organization (CRO) that conducts diverse clinical studies across pharmaceuticals, biotechnology, medical devices, investigator-initiated trials (IITs) and observational studies, guided by a people-centered mindset.



## Global Cancer Conference Season Begins... A Look at the 'Mainstream' Anti-Cancer R&D and Strategies

Anticancer R&D is shifting from single-mechanism approaches toward next-generation modalities such as ADCs, TCEs, TAT, and TPD. Precision therapies and alternative immuno-oncology strategies are expanding, while more candidates are entering clinical trials. As the global cancer market grows, investment and collaboration are accelerating, with companies moving faster to secure differentiated pipelines and strategic partnerships in emerging oncology fields.

## Global Technology Transfer Market Reshaping... China Emerges as Supplier of Innovation Pipeline

Chinese biotech companies are rapidly reshaping the global licensing market, expanding from 5% share in 2019–2021 to 48% in 2025. Backed by strong antibody, ADC, and bispecific pipelines, they are attracting large early-stage and mega-deals from global pharma. This shift signals a structural realignment in technology transfer, with China emerging as a major innovation and partnership hub.



## Statin combination drugs on the verge of overtaking monotherapy... 'Rosuvastava + Eze' spearheading the charge

주요 글로벌 암학회를 앞두고 항암 R&D 전략이 단일 기전에서 ADC, TCE, TAT, TPD 등 차세대 모달리티 중심으로 빠르게 이동하고 있다. 정밀 치료와 면역항암 대안 전략이 확대되며 임상 진입 후보도 증가하는 추세다. 이에 따라 투자와 공동개발 흐름도 빨라지고 있으며, 글로벌 항암 시장 성장과 맞물려 차세대 기술 경쟁이 더욱 치열해질 전망이다.





# newsletter



## Trump's pharmaceutical tariff order gives Korean biosimilar makers breathing room – for now

Korean drugmakers avoided the harshest U.S. pharmaceutical tariffs, and biosimilars received a one-year exemption, limiting immediate disruption. However, the new policy clearly favors companies with U.S. manufacturing, increasing pressure on Korean firms to localize production. For now, impact appears manageable, but future tariff reviews could reshape market access and strengthen the strategic value of onshoring.

## K-Bio Exports Record \$2 Billion in Q1.. Growth Continues

Korea's biopharmaceutical exports reached a record \$2 billion in the first quarter of 2026, rising 11.1% year on year and accounting for 71% of total pharmaceutical exports. Growth was driven by stronger CDMO competitiveness and expanding global market share, especially in Europe. Switzerland became the top export destination, while Korea also accelerated regulatory support to boost overseas expansion.



## Naphtha Anxiety Unresolved Despite Truce Spreads to Pediatric OTC Drugs

Rising oil prices and naphtha supply instability are putting pressure on Korea's OTC drug production, especially packaging materials for stick packs. Pharmaceutical firms are monitoring inventories closely, while pharmacies worry about shortages of pediatric fever reducer products. As existing stock runs down, the risk is shifting from temporary supply stress to broader structural instability, prompting calls for wider government reflection.

